Phone survey based RCT with low risk patients, 200 ivermectin
and 198 control, showing lower mortality, lower disease progression, lower
treatment escalation, and faster resolution of symptoms with treatment,
without reaching statistical significance. Authors find the results of this
trial alone do not support the use of ivermectin. However the effects are all
positive, especially for serious outcomes which are unable to reach
statistical significance with the very small number of events in the low risk
population.
An open letter, signed by >100 physicians, concluding this
study is fatally flawed can be found at
[jamaletter.com].
With the low risk patient population, there is little room for
improvement with an effective treatment - 59/57% (IVM/control) recovered
within the first 2 days to either "no symptoms" or "not hospitalized and no
limitation of activities"; 73/69% within 5 days. Less than 3% of all patients
ever deteriorated.
The primary outcome was changed mid-trial, it was originally
clinical deterioration, which is more meaningful, and shows greater benefit.
The new outcome of resolution of symptoms includes "not hospitalized and no
limitation of activities" as a negative outcome and is not very meaningful in
terms of assessing how much treatment reduces serious outcomes. Using this
measure could completely invalidate results - for example a treatment that
eliminates all COVID-19 symptoms but has a temporary minor adverse event
could be seen as worse.
Authors state that "preliminary reports of other randomized
trials of ivermectin as treatment for COVID-19 with positive results have not
yet been published in peer-reviewed journals", however there were 8
peer-reviewed RCTs with positive effects published prior to this paper(and 19
total peer-reviewed studies with positive effects).
Authors advised taking ivermectin on an empty stomach, reducing
lung tissue concentration by ~2.5x
[Guzzo].
76 patients were excluded due to control patients receiving
ivermectin. However, there was a similar percentage of adverse events like
diarrhea, nausea, and abdominal pain in both treatment and control groups.
These are potential non-serious side effects of treatment and suggest that it
is possible that many more control patients received some kind of
treatment.
No pre-registered protocol documentation has been found, the
same organization is associated with other COVID trials with extremely high
financial conflicts of interest with this trial, and the official registration
shows a different code to the paper (IVE-PA_CEIP vs. PI-CEP-1390)
[twitter.com].
Ivermectin was widely used in the population and available OTC
at the time of the study. The paper claims that patients were excluded if they
used ivermectin within the last 5 days, however this conflicts with the trial
registration which shows that use of ivermectin within the previous 2 days was
an exclusion criterion. A post-hoc change to 5 days was made on December 16,
2020
[clinicaltrials.gov, twitter.com (B)],
which is after enrollment ended (July 15 to November 30, 2020). Ivermectin
may retain efficacy far beyond 2 or 5 days. Note that, with 75% of patients
having symptoms for 4+ days at baseline, the trial registration allows
patients to take ivermectin for a few days after symptoms and then join the
placebo arm two days later
[twitter.com (C)].
This study reportedly has an ethical issue whereby participants
were told the study drug was "D11AX22"
[trialsitenews.com].
The editor-in-chief of JAMA initially offered to help with this issue, but
later indicated that "JAMA does not review consent forms", however the lead
author reportedly confirmed the issue
[francesoir.fr, trialsitenews.com (B), trialsitenews.com (C)].
The study protocol specifically allows "the use of other
treatments outside of clinical trials". The paper provides no information on
what other treatments were used, but other treatments were commonly used at
the time. Additionally, the control group did about 5x better than
anticipated for deterioration, also suggesting that the control patients used
some kind of treatment. Patients that enroll in such a study may be more
likely to learn about and use other treatments, especially since they do not
know if they are receiving the study medication.
The study protocol was amended 4 times. Amendments 2-4 are
provided but amendment 1 is missing. Amendment 2 increased the inclusion
criteria to within 7 days of onset, including more later stage patients and
reducing the expected effectiveness. The trial protocol lists “the duration
of supplemental oxygen” as an outcome but the results for this outcome are
missing.
RCTs have a fundamental bias against finding an effect for
interventions that are widely available — patients that believe they
need treatment are more likely to decline participation and take the
intervention
[Yeh], i.e., RCTs are more likely to enroll low-risk
participants that do not need treatment to recover (this does not apply to
the typical pharmaceutical trial of a new drug that is otherwise
unavailable). This trial was run in a community where ivermectin was
available OTC and very widely known and used.
Grants and/or personal fees, including in some cases during the
conduct of the study, were provided by Sanofi Pasteur, GlaxoSmithKline,
Janssen, Merck, and Gilead. For more details see
[trialsitenews.com (D)].
For other confounding issues see
[osf.io] and additional
issues can be found in the comments of the article
[jamanetwork.com].
Re-analysis of the raw data has been reported to show a significant positive effect
[twitter.com (D)].
Most data was collected via surveys, without physical
examination. 87% medication adherence.
NCT04405843 (history).
This is the
19th of 45 COVID-19 RCTs for ivermectin, which collectively show efficacy with
p=0.00000014.
This is the
41st of 96 COVID-19 controlled studies for ivermectin, which collectively show efficacy with
p<0.0000000001 (1 in 2 sextillion).
This study is excluded in the after exclusion results of meta
analysis:
strong evidence of patients in the control group self-medicating, ivermectin widely used in the population at that time, and the study drug identity was concealed by using the name D11AX22.
risk of death, 66.8% lower, RR 0.33, p = 0.50, treatment 0 of 200 (0.0%), control 1 of 198 (0.5%), NNT 198, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
|
risk of escalation of care, 60.8% lower, RR 0.39, p = 0.11, treatment 4 of 200 (2.0%), control 10 of 198 (5.1%), NNT 33, odds ratio converted to relative risk.
|
risk of escalation of care with post-hoc <12h exclusion, 34.3% lower, RR 0.66, p = 0.52, treatment 4 of 200 (2.0%), control 6 of 198 (3.0%), NNT 97, odds ratio converted to relative risk.
|
risk of deterioration by >= 2 points on an 8-point scale, 43.1% lower, RR 0.57, p = 0.37, treatment 4 of 200 (2.0%), control 7 of 198 (3.5%), NNT 65, odds ratio converted to relative risk, primary outcome.
|
risk of fever post randomization, 24.8% lower, RR 0.75, p = 0.38, treatment 16 of 200 (8.0%), control 21 of 198 (10.6%), NNT 38, odds ratio converted to relative risk.
|
risk of unresolved symptoms at day 21, 15.3% lower, RR 0.85, p = 0.53, treatment 36 of 200 (18.0%), control 42 of 198 (21.2%), NNT 31, inverted to make RR<1 favor treatment, odds ratio converted to relative risk, Cox proportional-hazard model.
|
lack of resolution of symptoms, 6.5% lower, HR 0.93, p = 0.53, treatment 200, control 198, inverted to make HR<1 favor treatment, post-hoc primary outcome.
|
relative median time to resolution of symptoms, 16.7% better, relative time 0.83, treatment 200, control 198.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|

López-Medina et al., 4 Mar 2021, Double Blind Randomized Controlled Trial, Colombia, peer-reviewed, median age 37.0, 19 authors, average treatment delay 5.0 days, dosage 300μg/kg days 1-5.
Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19
MD, MSc Eduardo López-Medina, MD Pío López, MD; Isabel C Hurtado, MD, MPH, DrPH Diana M Dávalos, MD, MPhil Oscar Ramirez, MD Ernesto Martínez, MD Jesus A Díazgranados, MD José M Oñate, MD, MS Hector Chavarriaga, MD Sócrates Herrera, PhD Beatriz Parra, PhD Gerardo Libreros, MD Roberto Jaramillo, MD; Dilian Ana C Avendaño, Dilian F Toro, DrPH Miyerlandi Torres, MD Maria C Lesmes, MD Carlos A Rios, MD Isabella Caicedo
JAMA, doi:10.1001/jama.2021.3071
IMPORTANCE Ivermectin is widely prescribed as a potential treatment for COVID-19 despite uncertainty about its clinical benefit. OBJECTIVE To determine whether ivermectin is an efficacious treatment for mild COVID-19. DESIGN, SETTING, AND PARTICIPANTS Double-blind, randomized trial conducted at a single site in Cali, Colombia. Potential study participants were identified by simple random sampling from the state's health department electronic database of patients with symptomatic, laboratory-confirmed COVID-19 during the study period. A total of 476 adult patients with mild disease and symptoms for 7 days or fewer (at home or hospitalized) were enrolled between July 15 and November 30, 2020, and followed up through December 21, 2020. INTERVENTION Patients were randomized to receive ivermectin, 300 μg/kg of body weight per day for 5 days (n = 200) or placebo (n = 200). MAIN OUTCOMES AND MEASURES Primary outcome was time to resolution of symptoms within a 21-day follow-up period. Solicited adverse events and serious adverse events were also collected. RESULTS Among 400 patients who were randomized in the primary analysis population (median age, 37 years [interquartile range {IQR}, 29-48]; 231 women [58%]), 398 (99.5%) completed the trial. The median time to resolution of symptoms was 10 days (IQR, 9-13) in the ivermectin group compared with 12 days (IQR, 9-13) in the placebo group (hazard ratio for resolution of symptoms, 1.07 [95% CI, 0.87 to 1.32]; P = .53 by log-rank test). By day 21, 82% in the ivermectin group and 79% in the placebo group had resolved symptoms. The most common solicited adverse event was headache, reported by 104 patients (52%) given ivermectin and 111 (56%) who received placebo. The most common serious adverse event was multiorgan failure, occurring in 4 patients (2 in each group). CONCLUSION AND RELEVANCE Among adults with mild COVID-19, a 5-day course of ivermectin, compared with placebo, did not significantly improve the time to resolution of symptoms. The findings do not support the use of ivermectin for treatment of mild COVID-19, although larger trials may be needed to understand the effects of ivermectin on other clinically relevant outcomes.
Funding/Support: This study received an unrestricted grant from Centro de Estudios en Infectología Pediátrica (grant ScDi823).
Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Group Information
References
Beigel, Tomashek, Dodd, ACTT-1 Study Group Members. Remdesivir for the treatment of COVID-19: final report, N Engl J Med,
doi:10.1056/NEJMoa2007764
Bray, Rayner, Noël, Jans, Wagstaff, Ivermectin and COVID-19: a report in antiviral research, widespread interest, an FDA warning, two letters to the editor and the authors' responses, Antiviral Res,
doi:10.1016/j.antiviral.2020.104805
Hashim, Maulood, Rasheed, Fatak, Kabah et al., Controlled randomized clinical trial on using ivermectin with doxycycline for treating COVID-19 patients in Baghdad, Iraq. medRxiv,
doi:10.1101/2020.10.26.20219345
Karaca-Mandic, Georgiou, Sen, Cao, Wang et al., A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19, JAMA Intern Med,
doi:10.1056/NEJMoa2001282
Mahajan, Larkins-Pettigrew, Racial demographics and COVID-19 confirmed cases and deaths: a correlational analysis of 2886 US counties, J Public Health (Oxf),
doi:10.1093/pubmed/fdaa070
Mastrangelo, Pezzullo, Burghgraeve, Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug, J Antimicrob Chemother,
doi:10.1093/jac/dks147
Mitjà, Corbacho-Monné, Ubals, -CoV-2 RESEARCH GROUP. Hydroxychloroquine for early treatment of adults with mild COVID-19: a randomized-controlled trial, Clin Infect Dis
Momekov, Momekova, Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens, Biotechnol Biotechnol Equipment,
doi:10.1080/13102818.2020.1775118
Niaee, Gheibi, Namdar, Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: a randomized multi-center clinical trial,
doi:10.21203/rs.3.rs-109670/v1
Rajter, Sherman, Fatteh, Vogel, Sacks et al., Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: the ICON Study, Chest,
doi:10.1016/j.chest.2020.10.009
Rodriguez, America's embrace of an unproven COVID treatment is hindering drug trials
Schmith, Zhou, Lohmer, Sanchez, Mejia-Fernandez et al., The approved dose of ivermectin alone is not the ideal dose for the treatment of COVID-19, Clin Pharmacol Ther,
doi:10.1002/cpt.1889
Siddiqi, Mehra, COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal, J Heart Lung Transplant,
doi:10.1016/j.healun.2020.03.012
Smit, Ochomo, Aljayyoussi, Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial, Lancet Infect Dis,
doi:10.1016/S1473-3099(18)30163-4
Tay, Fraser, Chan, Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5: protection against all 4 DENV serotypes by the inhibitor Ivermectin, Antiviral Res,
doi:10.1016/j.antiviral.2013.06.002
Wagstaff, Sivakumaran, Heaton, Harrich, Jans, Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochem J,
doi:10.1042/BJ20120150